Summary

The prowess of the nucleotide polymerase inhibitor sofosbuvir (SOF) against hepatitis C virus (HCV) is known. This article presents results from a study investigating a 12-week fixed-dose combination of SOF and nonstructural protein 5A (NS5A) inhibitor GS-5816 regimen in noncirrhotic, treatment-naïve HCV genotype 1 patients.